Processing

Please wait...

Settings

Settings

Goto Application

1. WO2019005559 - TDO2 AND IDO1 INHIBITORS

Publication Number WO/2019/005559
Publication Date 03.01.2019
International Application No. PCT/US2018/038508
International Filing Date 20.06.2018
IPC
C07D 471/08 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/-C07D463/251
02in which the condensed system contains two hetero rings
08Bridged systems
C07D 487/04 2006.1
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
487Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/-C07D477/183
02in which the condensed system contains two hetero rings
04Ortho-condensed systems
A61K 31/4188 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
41having five-membered rings with two or more ring hetero atoms, at least one of which is nitrogen, e.g. tetrazole
41641,3-Diazoles
4188condensed with heterocyclic ring systems, e.g. biotin, sorbinil
A61K 31/55 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
KPREPARATIONS FOR MEDICAL, DENTAL, OR TOILET PURPOSES
31Medicinal preparations containing organic active ingredients
33Heterocyclic compounds
395having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
55having seven-membered rings, e.g. azelastine, pentylenetetrazole
A61P 31/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/00 2006.1
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
CPC
A61P 31/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
31Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
A61P 35/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
35Antineoplastic agents
A61P 37/00
AHUMAN NECESSITIES
61MEDICAL OR VETERINARY SCIENCE; HYGIENE
PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
37Drugs for immunological or allergic disorders
C07D 221/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
221Heterocyclic compounds containing six-membered rings having one nitrogen atom as the only ring hetero atom, not provided for by groups C07D211/00 - C07D219/00
C07D 335/00
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
335Heterocyclic compounds containing six-membered rings having one sulfur atom as the only ring hetero atom
C07D 471/08
CCHEMISTRY; METALLURGY
07ORGANIC CHEMISTRY
DHETEROCYCLIC COMPOUNDS
471Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
02in which the condensed system contains two hetero rings
08Bridged systems
Applicants
  • GENENTECH, INC. [US]/[US]
  • PEI, Zhonghua [US]/[US] (MN)
  • PASTOR, Richard (MN)
  • GAZZARD, Lewis (MN)
  • PARR, Brendan [US]/[US] (MN)
  • LIU, Wendy [US]/[US] (MN)
  • MENDONCA, Rohan [US]/[US] (MN)
  • WU, Guosheng [US]/[CN] (MN)
  • YUEN, Po-Wai [US]/[CN] (MN)
Inventors
  • PEI, Zhonghua
  • PASTOR, Richard
  • GAZZARD, Lewis
  • PARR, Brendan
  • LIU, Wendy
  • MENDONCA, Rohan
  • WU, Guosheng
  • YUEN, Po-Wai
Agents
  • GREENFIELD, Michael, S.
Priority Data
PCT/CN2017/09052528.06.2017CN
Publication Language English (en)
Filing Language English (EN)
Designated States
Title
(EN) TDO2 AND IDO1 INHIBITORS
(FR) INHIBITEURS DE TDO2 ET IDO1
Abstract
(EN) Presently provided are inhibitors of cellularly expressed TD02 and IDO1, and pharmaceutical compositions thereof, useful for modulating an activity of tryptophan 2,3 dioxygenase and indoleamine 2,3-dioxygenase 1; treating immunosuppression; treating a medical conditions that benefit from the inhibition of tryptophan degradation; enhancing the effectiveness of an anti-cancer treatment comprising administering an anti-cancer agent; and treating tumor-specific immunosuppression associated with cancer.
(FR) La présente invention concerne des inhibiteurs de TDO2 et IDO1 exprimés de façon cellulaire, et des compositions pharmaceutiques de ceux-ci, utiles pour moduler une activité de la tryptophane 2,3 dioxygénase et de l'indoléamine 2,3-dioxygénase 1; traiter l'immunosuppression; traiter des états pathologiques qui sont améliorés par inhibition de la dégradation de tryptophane; augmenter l'efficacité d'un traitement anticancéreux consistant à administrer un agent anticancéreux; et traiter l'immunosuppression spécifique à une tumeur associée au cancer.
Related patent documents
Latest bibliographic data on file with the International Bureau